| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 15 Apr 2025 | 15 Apr 2025 |
| Dear Sir / Madam, Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are pleased to inform you that the Board of Directors of the company at their meeting held today (i.e. 15th April, 2025) which commenced at 03:00 P.M. and concluded at 03:30 P.M. have inter alia approved the following: 1. To appoint Mr. Harpreet Singh of M/s. S Harpreet and Associates, Chartered Accountants, as internal auditors of the company for the financial year 2024-2025. You are requested to kindly take the same on your record and acknowledge receipt. Thanking You. | ||
| Board Meeting | 14 Feb 2025 | 7 Feb 2025 |
| PRISM MEDICO AND PHARMACY LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2025 inter alia to consider and approve With reference to the captioned subject and in compliance with Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we wish to inform that the meeting of the Board of Directors of M/s. Prism Medico and Pharmacy Limited(hereinafter referred as the Company) is scheduled to be held at the registered office of the company i.e. Suketi Road Kala Amb Sirmaur Himachal Pradesh-173030 on Friday the 14th day of February 2025 at 01:30 P.M. inter alia to: - Consider approve and take on record the Unaudited Standalone Financial Results of the company along with the Limited Review Report for the quarter ended 31st December 2024 as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015. - Consider and discuss any other routine matter or business of the company. Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are pleased to inform you that the Board of Directors at their meeting held today (i.e. 14th February, 2025) which commenced at 01:30 P.M. and concluded at 05:00 P.M. have inter alia approved the following: The Board considered and approved the Unaudited Standalone Financial Results of the company for the quarter ended 31st December, 2024 along with the Limited Review Report duly signed by the Auditors of the company. You are requested to kindly take the same on record and oblige (As per BSE Announcement Dated on 14/02/2025) | ||
| Board Meeting | 14 Nov 2024 | 7 Nov 2024 |
| PRISM MEDICO AND PHARMACY LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2024 inter alia to consider and approve Consider approve and take on record the Unaudited Standalone Financial Results of the company along with the Limited Review Report for the quarter and half year ended 30th September 2024 as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015. Outcome of the Board Meeting. (As Per BSE Announcement dated on 14.11.2024) | ||
| Board Meeting | 5 Sep 2024 | 2 Sep 2024 |
| PRISM MEDICO AND PHARMACY LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/09/2024 inter alia to consider and approve ? To consider and approve the Directors Report along with all necessary annexures thereof for the Financial Year ended March 31 2024; ? To consider and fix day date time for holding the 22nd Annual General Meeting of the company and approve the notice of the same; ? To consider and fix the date for closure of Register of Members and Share Transfer Books for the purpose of Annual General Meeting; ? To appoint scrutinizer to conduct e-voting and poll process of 22nd Annual General Meeting of the company; ? To consider and recommend the re-appointment of M/s. Harjeet Parvesh and Company Chartered Accountants as the statutory auditors of the company. ? To recommend the appointment of Mr. Hitendra Shamji Hirani (DIN: 10427309) as a Director of the company. ? To recommend the appointment of Mr. Jay Hitendra Hirani (DIN: 10435245) as a Director of the company. ? To consider and discuss any other routine matter or business of the company. Dear Sir/Madam, Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find attached herewith outcome of meeting of Board of Directors held today (i.e. 05th September, 2024) which commenced at 04:00 P.M. and concluded at 07:30 P.M. Thanking You. (As Per BSE Announcement Dated on: 05/09/2024) | ||
| Board Meeting | 14 Aug 2024 | 7 Aug 2024 |
| PRISM MEDICO AND PHARMACY LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2024 inter alia to consider and approve 1. Consider approve and take on record the Unaudited Standalone Financial Results of the company along with the Limited Review Report for the quarter ended 30th June 2024 as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015. PURSUANT TO REGULATION 30 OF SEBI (LODR) REGULATIONS, 2015, WE ARE PLEASED TO INFORM YOU THAT THE BOARD OF DIRECTORS AT THEIR MEETING HELD TODAY I.E. 14TH AUGUST 2024 WHICH COMMENCED AT 12:30 P.M. AND CONCLUDED AT 01:30 P.M. HAVE INTER-ALIA APPROVED THE FOLLOWING 1. THE BOARD CONSIDERED AND APPROVED THE UN-AUDITED STANDALONE FINANCIAL RESULTS OF THE COMPANY FOR THE QUARTER ENDED 30TH JUNE 2024 ALONG WITH THE LIMITED REVIEW REPORT DULY SIGNED BY THE AUDITORS OF THE COMPANY Read less.. (As Per BSE Announcement Dated on 14.08.2024) | ||
| Board Meeting | 29 May 2024 | 22 May 2024 |
| PRISM MEDICO AND PHARMACY LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2024 inter alia to consider and approve - Consider approve and take on record the Audited Standalone Financial Results of the company along with the Auditors Report for the quarter and financial year ended 31st March 2024 as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015. - Consider and discuss any other routine matter or business of the company. Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are pleased to inform you that the Board of Directors at their meeting held today (i.e. 29th May, 2024) which commenced at 04:00 P.M. and concluded at 05:30 P.M. have inter alia approved the following: ? The Board considered and approved the Audited Standalone Financial Results of the company along with the Auditors Report for the quarter and financial year ended 31st March, 2024 as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. You are requested to kindly take the same on record and oblige. Thanking You. Read less.. (As Per BSE Announcement Dated on 29.05.2024) | ||
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
